Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis

dc.authorid0000-0002-5804-7552
dc.authorid0000-0002-1524-2809
dc.authorid0000-0003-4518-5283
dc.authorid0000-0002-2263-6689
dc.authorid0000-0003-0247-0332
dc.authorid0000-0002-2104-6783
dc.contributor.authorÇolak, Yaşar
dc.contributor.authorŞenateş, Ebubekir
dc.contributor.authorCoskunpinar, Ender
dc.contributor.authorOltulu, Yasemin Musteri
dc.contributor.authorZemheri, Ebru
dc.contributor.authorOzturk, Oguzhan
dc.contributor.authorDoganay, Levent
dc.date.accessioned2025-05-10T19:40:51Z
dc.date.issued2012
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractAim: In this study, we aimed to investigate the relationship between the histological fibrosis stage of nonalcoholic fatty liver disease (NAFLD) and serum connective tissue growth factor (CTGF) to determine the usefulness of this relationship in clinical practice. Methods: Serum samples were collected from 51 patients with biopsy-proven NAFLD and 28 healthy controls, and serum levels of CTGF were assayed by ELISA. Results: Levels of CTGF were significantly higher in patients with NAFLD compared with controls (P = 0.001). The serum CTGF levels were significantly increased, that correlated with histological fibrosis stage, in patients with NAFLD [in patients with no fibrosis (stage 0) 308.2 +/- 142.9, with mild fibrosis (stage 1-2) 519.9 +/- 375.2 and with advanced fibrosis (stage 3-4) 1353.2 +/- 610 ng/l, P < 0.001]. Also serum level of CTGF was found as an independent predictor of histological fibrosis stage in patients with NAFLD (beta = 0.662, t = 5.6, P < 0.001). The area under the ROC curve was estimated 0.931 to separate patients with severe fibrosis from patients with other fibrotic stages. Conclusion: Serum levels of CTGF may be a clinical utility for distinguishing NAFLD patients with and without advanced fibrosis.
dc.identifier.doi10.1155/2012/283726
dc.identifier.endpage83
dc.identifier.issn0278-0240
dc.identifier.issn1875-8630
dc.identifier.issue2
dc.identifier.pmid22846210
dc.identifier.scopus2-s2.0-84864420876
dc.identifier.scopusqualityN/A
dc.identifier.startpage77
dc.identifier.urihttps://doi.org/10.1155/2012/283726
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10127
dc.identifier.volume33
dc.identifier.wosWOS:000306651000003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofDisease Markers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectNonalcoholic fatty liver disease (NAFLD)
dc.subjectnonalcoholic steatohepatitis (NASH)
dc.subjectconnective tissue growth factor (CTGF)
dc.subjectfibrosis
dc.titleConcentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10127.pdf
Boyut:
1.43 MB
Biçim:
Adobe Portable Document Format